Overview

A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether fostamatinib is safe and effective in the treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).
Phase:
Phase 2
Details
Lead Sponsor:
Rigel Pharmaceuticals
Treatments:
Antibodies
Autoantibodies
Immunoglobulins